Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post-stroke epilepsy: a proof-of-concept, phase 2a, randomised, double-blind, p
a day ago
- #stroke
- #epilepsy
- #clinical trial
- Study investigated eslicarbazepine acetate for preventing seizures post-stroke.
- Phase 2a, double-blind, placebo-controlled trial in high-risk stroke patients.
- Primary endpoint: first unprovoked seizure, death, or discontinuation within 6 months.
- No significant difference in primary endpoint between treatment and placebo groups.
- Adverse events were similar in both groups, with hyponatraemia more common in treatment group.
- Trial underpowered due to slow recruitment and COVID-19 pandemic.
- Findings support feasibility of antiepileptogenesis studies for future trials.